Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
Relation Therapeutics Ltd bags US$35m in seed financing.
The latest financing round of generative AI drug discovery company Relation Therapeutics was led by DCVC and co-led by NVIDIA's venture arm,...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
Swiss vaccine developer Limma Tech get CARB-X grant
LimmaTech said, it will use the grant to advance preclinical development of its hexavalent vaccine candidate targeting Neisseria gonorrheae. Using...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...